Phase III, Multicenter, Randomized, Trial of CPX-351 (Cytarabine:Daunorubicin) Liposome Injection Versus Cytarabine and Daunorubicin in Patients 60-75 Years of Age With Untreated High Risk (Secondary) AML
Principal Investigator
Donna E. HoggeOverview
Body Locations and Systems
LeukemiaDisorders and Conditions
Acute Myeloid LeukemiaClinicalTrials.gov#
NCT01696084Status
Closed for RecruitmentStudy Start/End
Oct 1, 2012 to Feb 1, 2018Locations
Vancouver General HospitalName/Title
Mabel J.Y. Ma, Research AssistantPhone
604-537-1433Email Address
mabel.ma@alumni.ubc.caPurpose of Study
To confirm the efficacy of CPX-351 compared to 7+3 as first line therapy in elderly patients (60-75 yrs) with high risk (secondary) Acute Myeloid Leukemia. The primary efficacy endpoint will be overall survival.
Eligibility
Visit ClinicalTrials.gov for more information.
Disclaimer
Study Coordinators and Research Nurses cannot give medical advice over the phone. Telephone numbers and email addresses are provided for obtaining additional information on specific clinical research trials only. If you have specific questions which require clinical expertise, please call your primary care physician.